Paul O’Donohoe is Senior Director, eCOA Product and Science at Medidata Solutions, a clinical software platform provider. He is responsible for providing strategic oversight of the development of Medidata's electronic clinical outcome assessment technologies, and supporting internal teams and partners around the implementation of industry, regulatory and scientific best practices in clinical trials using mobile health technologies. He is passionate about developing the field of eCOA and mobile health through research and active involvement in industry consortia, and is currently the Industry Vice-Director of the C-Path ePRO Consortium.

Sonya Eremenco is Director of the Patient-Reported Outcome (PRO) Consortium. Sonya has over 20 years of experience in PRO (and other clinical outcome assessment) instrument development, with a focus on multicultural development, linguistic validation, and electronic implementation. Prior to joining C-Path’s PRO Consortium staff, Sonya was Director, ePRO New Products, at Evidera, Inc. She currently serves on the Steering Committee of ISOQOL’s Translation and Cultural Adaptation Special Interest Group. Sonya holds a Bachelor of Arts in Cultural Anthropology from Duke University and a Master of Arts in Multicultural Communication from DePaul University.

Lauren Oliva is US lead for Global Regulatory Policy at Biogen. She oversees the development and execution of R&D’s policy roadmap to advance Biogen’s neuroscience and rare disease portfolio. She is passionate about patient centric drug development and the impact of multi-stakeholder initiatives to advance the adoption of new technologies. Lauren is actively engaged with the Critical Path Institute, CTTI, and the National Academies’ Drug Forum. Lauren has over 10 years of experience in the pharmaceutical industry. She received her PharmD from Rutgers University, Ernest Mario School of Pharmacy and has previously served as adjunct faculty and lecturer at MCPHS University in Boston, MA.

Mr. Wenzel worked for Parexel for over fifteen years. His background includes product, corporate, and personnel management; sales and marketing; and information systems experience. These skills have been applied within the life sciences and health care industries through working with and for contract research organizations, technology partners and clinical trial sponsors. His areas of subject matter expertise include electronic clinical outcomes assessment, patient sensors and a broad range of eClinical technology used within clinical drug trials. He has been on the program committee of several Drug Information Association meetings and is chairing a session at this year’s DIA Annual Meeting.

Julie Dietrich is the Vice President of Clinical Operations at Genfit Corp. Leading this function from clinical program design through study execution allows for the introduction of innovative approaches for clinical research, including new uses of digital solutions. She has led company-wide initiatives related to patient centricity and evidence generation planning and is committed to collaborating with patients throughout drug development. Julie has over 20 years of experience in the biopharmaceutical industry, previously holding Clinical Development and Medical Affairs positions at Amgen and Bristol-Myers Squibb.

Harlan Krumholz, the Harold H. Hines, Jr. Professor of Medicine at Yale School of Medicine, is a cardiologist and Director of the Yale Center for Outcomes Research and Evaluation. He is an expert in the science to improve the quality and efficiency of care, reduce disparities, and improve integrity in medical research. He founded HugoHealth, a patient-centric platform to engage people as partners in research and leverage the secure movement of digital health data. He is a member of the National Academy of Medicine, American Society for Clinical Investigation, and Association of American Physicians. He received a BS from Yale, an MD from Harvard, and a Masters in Health Policy and Management from the Harvard School of Public Health.

Mr. Andrus brings over 25 years of executive management, operational, quality, and business experience to CRIO. Most recently he served as Chief Strategy Officer for Clinical Ink. Prior to that, he served as Senior Vice President for BioClinica (now Clario), where he led the e-clinical operations and data management teams. His early career includes experience in pharmaceutical consulting and contract research organizations. Andrus serves on the board and executive committee of the Society for Clinical Data Management (SCDM), is a co-lead with the Decentralized Trials and Research Alliance (DTRA) workstream initiative, serves as co-author on eCOA Consortium publications, and has been on the advisory boards of CDISC and DIA.

Jennifer Goldsack is the Chief Executive Officer of the Digital Medicine Society (DiMe). Founded in 2019, DiMe is the first professional organization for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health. DiMe is a 501c3 non-profit organization dedicated to advancing digital medicine to optimize human health. We do this by serving professionals at the intersection of the global healthcare and technology communities, supporting them in developing digital medicine through interdisciplinary collaboration, research, teaching, and the promotion of best practices.

Dr. Mitchel is a President and CEO of THI Pharma Services. He also created the team at Target Health developing software tools to enable the “Paperless Clinical Trial.” Dr. Mitchel recently served on the Executive Committee of CTTI where he represented the Steering Committee. Dr. Mitchel has held positions at Ayerst Laboratories, Pfizer Laboratories and Pfizer Consumer Health Care. Dr. Mitchel is currently Adjunct Professor of Pharmacology and Toxicology at the Ernest Mario School of Pharmacy (Rutgers), Adjunct Clinical Professor in the Department of Dermatology (SUNY Stony Brook School of Medicine) and Lecturer at New York Medical College.

J. Jason Lundy, PhD is a measurement scientist specializing in the development and analysis of COAs. Before co-founding Outcometrix, Jason was the Director of the ePRO Consortium and the Associate Director of the PRO Consortium at C-Path. In these roles, Jason worked on numerous COA qualification projects in collaboration with FDA and industry colleagues. His experience navigating the DDT Qualification process provided the opportunity to engage in frequent FDA discussions on the evidence needed for the regulatory review of COA measures.

Paul has 25 years of experience in medical device R&D, strategic marketing, product management, clinical research, and medical informatics. Prior to Roche / Genentech, Paul was with Becton Dickinson, as Worldwide Director of Strategic Marketing. Prior to that role, Paul was the head of Product at WellDoc, Inc., where he led the product management activities for WellDoc’s portfolio of mobile health solutions. He was responsible for WellDoc’s landmark BlueStar™ product, a class II medical device and the world’s first reimbursed, prescription-only software for diabetes. Paul holds four issued patents in medical software and drug delivery devices and is also a co-author of numerous peer-reviewed articles in medical informatics and diabetes.

Kristen Valdes is the founder and CEO of b.well. Kristen is a transformative force in today’s healthcare marketplace, spearheading the conversation on how empowering consumers can transform healthcare delivery. She is a seasoned healthcare executive with over 20 years in the industry and has dedicated her life to pioneering inventive solutions. This quest has been largely driven by her powerful personal story as the mother of a child suffering from a significant autoimmune disorder. Prior to founding b.well, Kristen was a Vice President at United Healthcare running Medicare Advantage plans across 12 states.

Mr. Dan Tierno has over 20 years of experience in the pharmaceutical and biotech industry, specializing in drug development, data sciences and analytics for clinical trials, and commercialization of novel small molecule and cell based therapeutics. Mr. Tierno has spoken on training scientists for rare disease therapeutic development, innovations in drug development and clinical trials, commercialization of cell and gene therapies as well as defining and generating value via portfolio management. Mr. Tierno holds his Honors M.B.A. from the Zicklin School of Business at Baruch College, and his M.A. in Biotechnology from Columbia University.

James Beck, PhD, has led the scientific affairs of the Parkinson's Foundation since 2008. Dr. Beck oversees the Foundation’s research strategy and programs, including management of clinical research, grants that support research centers, individual investigators, fellows and collaborative projects. Dr. Beck is currently an Adjunct Associate Professor in the Department of Neuroscience and Physiology at the New York University School of Medicine. Dr. Beck holds a BS from Duke University and a PhD from the University of Washington, Seattle. He completed his postdoctoral training at the New York University School of Medicine.

With over twenty years of experience working in the pharmaceutical, CRO, and site sectors, Dan has gained a wide perspective and understanding of the needs of the industry as a whole that aid to facilitate and build strong alliances. His focus is on expanding SCRS’ global footprint and the inclusion of all industry stakeholders in SCRS initiatives with the goal to foster sustainability for clinical research sites.

Matt is Vice President of Product at Medidata Solutions, and has lead Medidata's Patient Cloud solution for the last 7.5 years. During this time, Matt has lead product strategy and overseen development for Medidata's eCOA, eConsent, Wearable Sensor, and Virtual Trial capabilities. Matt lives in Brooklyn, NY with his wife and daughter.

Rachel Chasse is a Digital Operations Lead at AbbVie. operationalizing digital health technologies for success in clinical trials. Previously, she was the founding Director of Innovation at the Digital Medicine Society (DiMe), fostering collaboration and connection within the digital medicine field, leading DiMe's scientific programming and strategic vision. Before DiMe, Rachel worked in the Digital Medicine group at Pfizer, operationalizing digital innovation for inclusion within clinical trials. Before Pfizer, she worked in dementia research supporting patients and their families at Washington University in St. Louis where she earned her Master of Science in Clinical Research Management.

Mike Benecky joined GSK in October 2011 as Senior Director, Global Regulatory Affairs in located in Research Triangle Park, North Carolina. Mike is a Subject Matter Expert in the Regulatory Aspects of Digital Medicine. Successful projects at GSK included launch of the MyAsthma mobile medical device app in the UK, execution of the PARADE Virtual Clinical Study in Rheumatoid Arthritis Patients and implementation of digital adherence technology within respiratory medicine clinical trials. In April 2020, Mike joined UCB as a Senior Director, Global Regulatory Affairs where he provides regulatory strategy for UCB Teams seeking to implement wearable sensor technology in clinical trials.

Elizabeth (Nicki) Bush is Associate Vice President and Head of Patient-Focused Endpoints and Measurement at Eli Lilly and Company, responsible for the design and implementation of patient-centered measurement strategies to support drug development efforts across Lilly’s portfolio. In this capacity, she and her team advise on the selection, modification and development of clinical outcome assessments (COAs) for use in clinical trials and other research studies, and utilize mixed methods approaches to evaluate the measurement properties of COAs as well as aid in interpretation of the resultant data. Nicki has held patient-centered measurement research and leadership positions in both consultancy and industry.

Ariel V. Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices in clinical trials across the organization. She was previously a Senior Clinical Data Scientist at Biogen where she managed the wearable sensors deployed in clinical trials for Parkinson’s Disease. Ariel was the algorithm team lead at MC10 Inc and a senior research scientist at BioSensics LLC. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and an AB and BE in Mechanical Engineering from Dartmouth College. She currently serves on the Strategic Advisory Board of the Digital Medicine (DiMe) Society.

Melissa's role is part of the Patient Informed Development and Health Value Translation Team, she is overseeing primarily the Neurology portfolio. This role is the face of Sanofi R&D to external Patient Advocacy organizations. A major responsibility of this role is to drive the patient voice into effective clinical development strategies with measurable impact for the portfolio which seeks to differentiate Sanofi products, increase product value, and accelerate time to new treatment options for patients. She joined the Patient Insights team 3 years ago, bringing over 15 years in the pharmaceutical industry with various leadership experience in the management and oversight of trial operations among multiple therapeutic areas and phases.

As Senior Infrastructure and Security Architect, John is responsible for ensuring the inherent security, availability, and reliability of Clinical Ink's platforms, including the adoption of cloud-based services for delivering eSource, eCOA, and ePRO capabilities. Mr. Edwards has over 25 years implementing and supporting various information technologies in both the public and private sectors, more than half of which has focused on security and compliance.

At Biogen, Kelley oversees a portfolio of projects aimed developing, validating, and implementing novel clinical measurements for neuromuscular disease programs across the portfolio, including ones implemented with digital health technology. He holds a B.S. in mechanical engineering from Lehigh University and a Ph.D. in anatomy and neurobiology from Boston University School of Medicine.

Dan Gottlieb is a clinical informaticist, software consultant, and trainer focused on helping developers and organizations leverage FHIR-based standards. Working with Harvard Medical School, Boston Children's Hospital (BCH), and other commercial and non-profit organizations, he has created and deployed healthcare apps, clinical decision support services and population health analytic tools. Building on this experience, he collaborates with developers around the world to design and improve open standards through the HL7 organization, and the Argonaut and SMART Projects. An experienced software developer, he has led software teams at BCH, the New York City Department of Health, and JPMorgan. Dan has a masters degree in health policy from NYU.

Jonathan S. Helfgott is Faculty/Program Coordinator for the MS in Regulatory Science program at Johns Hopkins University where he teaches and advices students. Additionally, he is the Executive Director at Stage 2 Innovations. Prior to joining Stage 2 Innovations in early 2015, Mr. Helfgott was formerly the Associate Director for Risk Science, within the Office of Scientific Investigations at FDA’s Center for Drug Evaluation & Research (CDER). Prior to joining CDER in 2010, Mr. Helfgott worked at the FDA’s Center for Devices and Radiological Health (CDRH) within the Division of Bioresearch Monitoring (BIMO).

Ryan Howells is a Principal at Leavitt Partners. Ryan has worked with the White House, VA, CMS, CCIIO, ONC, & OCR on health care issues & is a frequent speaker at major industry events. Ryan currently helps lead the CARIN Alliance, a multi-sector, public-private alliance focused on providing consumers digital access to their health information. Ryan is a member of the CMS Medicaid Information Technology Architecture (MITA) Governance Board, Carequality's Steering Committee, ONC's Digital Identity Taskforce, and board observer for a major technology company. Ryan received his master’s in health administration from USC where he was a Dean’s Merit Scholar & bachelor’s degree in English from BYU.

Ahmad Namvargolian co-founded Care Access in 2015 which quickly grew into one of the most trusted clinical research companies in the US. His one core mission for Care Access is to remove barriers in clinical research for sponsors, physicians, and patients; making clinical research accessible to all. Care Access offers a unique industry solution delivering on complex decentralized trials, taking clinical research directly to patients by deploying mobile site infrastructure and “Jump Teams” around the country to create pop-up research infrastructure, on demand, wherever they are needed. Namvargolian holds a Master's Degree in Public Policy and a Bachelor's degree in Bioengineering and Material Science.

Bray was the Director of Strategic Partnerships at Evidation Health. She develops collaborations to support the design and implementation of participant-centered studies and measures, and serves on the All of Us National Advisory Panel and the Digital Medicine Society Scientific Leadership Board. Previously, Bray served on the National Academies of Sciences, Engineering, and Medicine (NASEM) Health Science Policy Board, led engagement for the Duke Clinical Research Institute Project Baseline Study Coordinating Center, and served as co-chair on the Advisory Committee to the NIH Director that authored the Precision Medicine Initiative's Cohort Program. Bray holds a BS degree from the University of Georgia and MFS from National University.

Dr. Peterson has extensive experience with the application of actigraphy and physiological measurements in pharmaceutical clinical trials. After 20 years of academic research on acute lung injury and respiratory measurement techniques, he joined Pfizer's Clinical Technology group to develop and validate technologies for clinical trials. Eleven years later he joined Philips Respironics to develop actigraphy analysis algorithms and promote the use of wearable devices in clinical trials. He also joined the Clinical Trials Transformation Initiative (CTTI) and helped write the recommendations to the FDA on the use of wearable devices in clinical trials (2018). He is now an independent consultant and CTTI member.

Dr. Schneider graduated from Brown University in 2006 and received her MD from the University of Rochester School of Medicine and Dentistry in 2010. She remained at the University of Rochester completing a neurology residency in 2014 and a movement disorders fellowship in 2015. She specializes in the care of patients with movement disorders, including Parkinson's disease, essential tremor, and dystonia. Her primary research interests include the assessment and treatment of neuropsychiatric features of neurodegenerative diseases and the use of novel tools and technology to enhance clinical care and further research.

Kate Zarzar is a Principal PCOR Scientist and Head of Agile Execution focused on designing and delivering COA strategies at Roche. As head of Agile Execution, she focuses on leveraging agile methodology to improve how the business executes paper COA and eCOA strategies to generate patient-relevant evidence. Prior to joining Roche eight years ago, Kate spent six years at TransPerfect leading the design and oversight of linguistic validation programs for a variety of sponsors. Kate specializes in global cross-functional and cross-industry partnerships to drive improvement in the development and implementation of COA strategies. Kate is passionate about enabling further understanding and insight into the patient experience.

Bill is an eCOA scientist and VP of product intelligence and positioning at Signant Health. He has worked in the Pharmaceutical industry for over 30 years and is the author of over 70 publications and two industry textbooks on ePRO. His recent scientific work includes the use of wearable technology and BYOD eCOA in clinical trials. Bill is an active member of the C-PATH ePRO Consortium, is a member of the scientific leadership board of the Digital Medicine Society, and leads a group on wearable technology within DIA's Study Endpoints Community. Bill provides eClinical commentary on LinkedIn and Twitter (@billbyrom).

Seya Colloud is a pharmacist by training and holds a Masters in International Drug Regulatory affairs from University Paris-Sud, (France). She works as Global Regulatory Director in the personalized healthcare team for F. Hoffmann La Roche in Switzerland. Her area of expertise and interest include medicine and digital health regulations. She is particularly interested in the regulatory frameworks at the interface between software as medical device and medicinal product development, including novel outcomes to measure diseases.

Jessilyn Dunn is an Assistant Professor of Biomedical Engineering and Biostatistics & Bioinformatics at Duke University. Her primary areas of research focus on biomedical data science and mobile health; her work includes multi-omics, wearable sensor, and electronic health records integration and digital biomarker discovery. She is currently PI of the CovIdentify study to detect and monitor COVID-19 using mobile health technologies. Dr. Dunn was an NIH Big Data to Knowledge (BD2K) Postdoctoral Fellow at Stanford and an NSF Graduate Research Fellow at Georgia Tech and Emory, as well as a visiting scholar at the US Centers for Disease Control and Prevention and the National Cardiovascular Research Institute in Madrid, Spain.

Cindy Howry is nationally recognized thought-leader in the area of eCOA which empowers the patients and engages them to maintain and improve their health, simultaneously enabling clinical teams to have real-time access to better quality clinical data. Ms. Howry has more than 38 years of experience in management and leadership, including 19 years in the eCOA industry. Currently, she is CEO at assisTek.

Dan joined MindMed as Chief Medical Officer in February 2021 following MindMed’s acquisition of HealthMode, the company he co-founded and led as CEO. Prior to HealthMode, he built and led clinical, informatics, and regulatory strategy for Pfizer’s Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer.

Currently leading a small team of technologists exploring innovative technologies to support Life Sciences R&D. It is a blast! Topic areas include: AI / Data Science, IoT, Lab Automation, AR/VR, Digital Product Development, Digital Devices in Clinical Trials, Blockchain, FAIR Data Areas of Expertise: Leading Organizational Change Digital Transformation Innovation Methodologies Project Management GxP Validation Full Software Development Lifecycle Specialties: German - Level B1

JP Pollak is co-founder and Chief Architect of The Commons Project, Sr Researcher in Residence at Cornell Tech, and Assistant Professor at Weill Cornell Medicine. He is currently focused on CommonHealth, the Android equivalent to Apple Health. JP is a builder and researcher helping individuals collect all aspects of health data for research and care. Prior to joining TCP, he founded Curiosity Health to better support early stage, digitally-enabled clinical research; founded Wellcoin, an award-winning consumer health incentives application; and built numerous applications in health and life sciences that are widely used in research and business. JP earned his PhD in Information Science at Cornell University.

I am a member of the PBCers Organization's Executive Committee (which is an all volunteer organization), as well as a person living with Primary Biliary Cholangitis for over 20 years. My responsibilities with the organzation include making decisions with other members of the committee on the day to day activities of the organization as well as managing our social media sites in offering support to our membership.

Karlin Schroeder, M.A., is the Associate Vice President of Community Engagement at the Parkinson’s Foundation, where she leads the Research Advocacy program. Through this program, Karlin creates and directs projects to incorporate patient expertise into research design and implementation with industry, academic centers and government. Her special interests include metrics and improving diversity in patient engagement in research. She is a steering committee member with the Clinical Trials Transformation Initiative, working on the Quality by Design initiative. She is also a member of Patient Focused Medicines Development. Karlin has a B.S. in psychobiology and psychology and an M.A in health advocacy.

Veronica Contreras works at ERT, a Global Data Management Technology Company, headquartered in Philadelphia, PA, and is the company's global Data Privacy Officer, Counsel. Veronica is responsible for the company's data privacy compliance program, including without limitation: compliance with GDPR, HIPAA , CCPA compliance; on-going administration (and maintenance) related to data privacy policies and procedures, privacy (and security) risk assessments, data privacy compliance training, and client-related audit requirements. A lawyer by training, Veronica earned her JD from the Western Michigan Cooley Law School and her BA from the University of Wisconsin - Madison.

Luca is the Co-founder and Chief Data Scientist at Evidation Health, responsible for data analytics and research and development. At Evidation he has driven research collaborations resulting in numerous publications in the fields of machine learning, behavioral economics, and medical informatics. Previously, Luca held research positions in industry and academic institutions, including Ask.com, Google, ETH Zurich, and UC Santa Barbara. He has co-authored several papers and patents on efficient algorithms for partitioning and detecting anomalies in massive networks. Luca holds MS and PhD degrees in Computer Science from UC Santa Barbara, and ME and BE degrees from the Sant’Anna School of Pisa, Italy.

Tom Haag has a truly innovative vision for quality in clinical research that is focused on delivering outcome data that justifies therapeutic costs. Formerly the Global Head of Digital Development and Transformation QA with Novartis, Tom led on end-to-end quality and data integrity oversight for all Novartis digital development and new technology initiatives. This included transition to an e-technology-ready quality management system for the Novartis clinical trial process. More recently, he was the VP of Quality Assurance at CRF Health, where he focused on Data Integrity improvements around the company’s ePRO and eConsent services. He established Cardinal Solutions Consulting, LLC in November 2018.

Deven McGraw is the Chief Regulatory Officer for Ciitizen, a consumer health technology start-up. Prior to joining Ciitizen, she directed U.S. health privacy and security through her roles as Deputy Director, Health Information Privacy at the HHS Office for Civil Rights (the office that oversees HIPAA policy development and enforcement) and Chief Privacy Officer (Acting) of the Office of the National Coordinator for Health IT. Widely recognized for her expertise in health privacy and security, she directed the Health Privacy Project at the Center for Democracy & Technology (a nonprofit civil liberties organization) for six years and led the privacy and security policy work for the HITECH Health IT Policy Committee.

Daniel Novak, Ph.D. is a Person with Parkinson's and a volunteer for the Parkinson's Foundation where he currently serves as a research advocate, grant reviewer and community volunteer. Previously, he served as the national Chair for the People with Parkinson’s Advisory Committee, Parkinson’s Foundation. He has served as reviewer for PCORI and as a leadership consultant specializing in organizational diagnosis and collaboration. Dr. Novak retired from academia as Department Chair where he led MBA, MPA and doctoral-level research programs. Prior to his academic career, he served thirty-one years at IBM in national and international roles in life sciences, healthcare digital imaging, social network analysis, virtual teams and innovation.

JJames Riddle is the Senior Vice President of Global Review Operations at Advarra, the world’s largest provider of ethics, safety, and compliance oversight reviews services. With 25+ years’ experience providing support to the clinical research community, Riddle has operational responsibility for Advarra’s global review services including IRB, IBC, DMC, EAC. In this role, he helps sponsors, CROs, and research sites advance clinical research with a mission to improve human health. Riddle is a regular speaker at industry events and has written abundantly on research compliance and efficiency topics. He is also a member of CTTI, NWABR, SASI, and PRIM&R.

Dr. Isaac R. Rodriguez-Chavez is a biomedical and regulatory leader with expertise in Infectious Diseases, Viral Immunology, Viral Oncology, Microbiology, and Vaccinology. His experience covers the entire life cycle of medical products from basic, preclinical, interventional clinical research (phase I – IV), non-interventional clinical research and post-marketing studies.

Todd Albin joined the founding of Cedar Health Research following more than two decades of experience as an accomplished leader in the clinical research industry. He is an expert in the areas of clinical research site operations and patient engagement. His past experience includes management roles with Synexus, PPD/Acurian, and Ora where he led global teams supporting operations, investigator site relations, and patient recruitment and retention. Todd is a Certified Clinical Research Professional, received is bachelors in business administration from the University of Miami and his MBA from Florida International University.

Channing Barker visualizes a world free of MS for everyone impacted by this disease. Diagnosed with MS at age 16, she has since volunteered countless hours to work toward that end at events and in public policy as an MS Activist at the state and federal level. In her professional life, Barker followed her dreams as a journalist in broadcast TV as a morning show anchor in Northwest Arkansas. While wanting to protect her health, Channing took on a new role in 2017 and now serves as the Director of Communications for Benton County, Arkansas.

My passion is to improve the lives of patients by supporting the development and deployment of novel medical devices and drug therapies. My passion has led me to develop a deep and broad knowledge of the development and use of technology to improve patient outcomes, and how regulatory affairs and quality assurance can be used as tools to promote best in class product development, improve time to market and increase patient safety. I have In following my passion, I have been privileged to work with some great organizations including over 10 years at Abbots Labs, 5 years at Boston Scientific, Fujifilm Medical Systems, Becton Dickinson and, of course, Clinical Ink where I was head of Quality and regulatory.

Tom is a Principal Scientist and Digital Health Lead in Genentech's Research and Early Development Informatics group.  His current focus is on developing technology platforms supporting molecule teams across the early development portfolio.  Tom has over 24 years of clinical development experience, including 8 years of experience in developing and deploying digital technologies in clinical trials. He has been at Roche since 2010 serving in a variety of roles within Clinical Operations and Innovation groups. An Exercise Physiologist by training, he has been continuously tinkering with the various digital gadgets on himself before testing them on other people. He lives in San Mateo, CA with his wife Elizabeth and 4 children.  

Betsy Williams is a Director in the Patient Centered Endpoints group at IQVIA, where she provides scientific advice and leadership to ensure that the patient's story is appropriately captured in research activities. Betsy has over 20 years of experience in the pharmaceutical and medical device industry, previously holding Clinical Development and Medical Affairs positions at Eisai, Upsher-Smith Laboratories, Dainippon-Sumitomo Pharma, Yamanouchi Pharma USA, Merck, and Boston Scientific. She received her PhD in biological engineering from Mississippi State University.

Dr. Elizabeth Esterl is the VP Operations and Research at ClinOne, Inc. and has spent most of her career in the academic clinical research arena where she developed and implemented two successful clinical trials organizations~ overseeing +900 clinical research studies to deliver cutting-edge research, clinical care, and a voting member of the pediatric panel on a multiple institutional review board. Dr. Esterl is a Professor of graduate-level Nursing Research at the University Medical and Pharmacy School in Ho Chi Minh, Vietnam. “I’ve dedicated my career to leading clinical trial programs within academic institutions and I am now helping research sites and sponsors to modernize clinical trials, using technology with a global footprint”